[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling

In the completed phase I trial NCT01450384 combining the anti-folate pemetrexed and the multi-kinase inhibitor sorafenib it was observed that 20 of 33 patients had prolonged stable disease or tumor regression, with one complete response and multiple partial responses. The pre-clinical studies in thi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Booth, Laurence, Roberts, Jane L., Tavallai, Mehrad, Chuckalovcak, John, Stringer, Daniel K., Koromilas, Antonis E., Boone, David L., McGuire, William P., Poklepovic, Andrew, Dent, Paul
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5029651/
https://ncbi.nlm.nih.gov/pubmed/27015562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8281
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars